Clinical trials · New York
Advanced or Metastatic Solid Tumors clinical trials in New York
We’re tracking 582 recruiting advanced or metastatic solid tumors studies with a site in New York — including Phase 1, Phase 1/Phase 2, Phase 2, Phase 2/Phase 3 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in New York
- NCT06324357RecruitingPhase 1/Phase 2
Zongertinib for HER2-positive cancers that have spread
This trial tests a new pill called zongertinib, alone or with other drugs, for people with HER2-positive cancers (like breast, stomach, or colorectal cancer) that have spread and are no longer responding to standard treatments. The goal is to find the best dose and see if it can help shrink tumors or slow the disease.
New York, New YorkAges 18 years+ - NCT06264180RecruitingPhase 3
Viral therapy and nivolumab for advanced melanoma
This trial tests a combination of an investigational viral therapy (VO) and the immunotherapy nivolumab for people with advanced melanoma that has stopped responding to previous anti-PD-1 and anti-CTLA-4 treatments. The goal is to see if this combination works better than other standard treatments your doctor might choose.
Stony Brook, New YorkAges 12 years+ - NCT06129864RecruitingPhase 3
Study of Volrustomig for advanced head and neck cancer after chemoradiation
This trial tests a new drug called volrustomig (MEDI5752) for people with advanced head and neck cancer that was not removed by surgery and has been treated with chemoradiation. The goal is to see if the drug can help prevent the cancer from coming back.
Stony Brook, New YorkAges 18–130 - NCT06118086RecruitingPhase 1/Phase 2
Study of REM-422 for advanced adenoid cystic carcinoma
This trial tests an experimental drug called REM-422 for people with adenoid cystic carcinoma (ACC) that has spread, come back, or cannot be removed by surgery. The study has two parts: an early part for people with advanced ACC and a later part for those with a specific genetic change (MYB biomarker) in their tumor. The goal is to see if REM-422 can slow or stop cancer growth.
New York, New YorkAges 18 years+ - NCT06112314RecruitingPhase 3
New immunotherapy combo for advanced melanoma (first treatment)
This trial tests a new immunotherapy drug (IMC-F106C) combined with standard treatments against the usual nivolumab-based therapy for people with advanced melanoma who have not been treated before. It's for people who carry a specific immune system marker (HLA-A*02:01) and are in fairly good health.
New York, New YorkAges 18 years+ - NCT06121180RecruitingPhase 2
Cemiplimab plus ziv-aflibercept for metastatic uveal melanoma
This trial tests two drugs, cemiplimab and ziv-aflibercept, together for people whose uveal melanoma has spread. It may be an option if previous treatments have stopped working or you haven't had treatment yet.
New Hyde Park, New YorkAges 18 years+ - NCT06099769RecruitingPhase 2
Testing enzalutamide with or without mifepristone for AR-positive breast cancer
This trial tests if adding the drug mifepristone to the standard antiandrogen enzalutamide works better than enzalutamide alone or chemotherapy for people with a specific type of breast cancer that has androgen receptors. It aims to find a new targeted treatment option for triple-negative or ER-low breast cancer.
New York, New YorkAges 18 years+ - NCT06064877RecruitingPhase 3
Study of ficlatuzumab plus cetuximab for advanced head and neck cancer
This trial tests a combination of two drugs, ficlatuzumab and cetuximab, for people with recurrent or metastatic head and neck cancer that is HPV-negative and has not responded to prior immunotherapy and chemotherapy. It aims to see if this combination can help shrink tumors or slow the disease.
New York, New YorkAges 18 years+ - NCT06079671RecruitingPhase 3
Volrustomig for high-risk locally advanced cervical cancer
This trial tests a new medicine called volrustomig for women with locally advanced cervical cancer that has not spread. It is given along with standard chemoradiation and aims to improve outcomes.
Syracuse, New YorkAges 15 years+ - NCT05815173RecruitingPhase 1
Ladarixin plus sotorasib for KRAS-mutated lung cancer
This Phase 1 trial tests whether ladarixin combined with sotorasib can help people with advanced or metastatic non-small cell lung cancer (NSCLC) that has a KRAS G12C mutation. It’s mainly testing safety and how well the treatments work after the cancer has progressed despite prior anti–PD-1 treatment.
Garden City, New YorkAges 18–100 - NCT05673148RecruitingPhase 2
Adding targeted tumor treatment to standard therapy for limited metastatic colorectal cancer
This trial tests whether adding a precise, targeted treatment to destroy remaining cancer spots (called total ablative therapy) after initial chemotherapy can improve outcomes for people with limited metastatic colorectal cancer. It aims to see if this extra treatment is safe and effective.
Brooklyn, New YorkAges 18 years+ - NCT05624996RecruitingPhase 3
Targeted high-dose radiation added to standard lung cancer treatment
This trial tests whether adding high-dose, targeted radiation to the usual treatment helps people with locally advanced, non-operable lung cancer live longer or better control the cancer. It may help shrink tumors in the chest and improve outcomes when surgery can’t be done.
Staten Island, New YorkAges 18 years+ - NCT05549297RecruitingPhase 3
Tebentafusp plus choice of treatment for advanced melanoma
This Phase 3 study compares tebentafusp treatment against the doctor’s choice of standard options in people with previously treated advanced melanoma. It aims to see which approach works better for controlling the cancer and improving outcomes.
Lake Success, New YorkAges 18 years+ - NCT05376553Enrolling by invitationPhase 1
Test cemiplimab plus chemo before treatment for head and neck cancer
This Phase 1 trial tests cemiplimab (an immune system medicine) given with “induction” chemotherapy before the main treatment for locally advanced squamous cell head and neck cancer. It’s designed to see how well this treatment is tolerated and to learn about immune responses that may help future patients.
New York, New YorkAges 18 years+ - NCT05398484RecruitingPhase 2/Phase 3
Psilocybin therapy for advanced cancer-related anxiety
This trial studies whether psilocybin (with support and therapy) can reduce anxiety in people with advanced cancer. It may help with distress and quality of life, while the study team monitors safety closely.
New York, New YorkAges 21–100 - NCT05099172RecruitingPhase 1/Phase 2
Targeted therapy for advanced lung cancer with EGFR or HER2 changes
This trial tests a new targeted drug for people with advanced non-small cell lung cancer that has specific genetic changes (EGFR or HER2). The drug may slow cancer growth and help you live longer.
Buffalo, New YorkAges 18 years+ - NCT04929223RecruitingPhase 1
Targeted drug study for metastatic colon or rectal cancer
This Phase 1 study tests targeted cancer treatments in people with metastatic colorectal cancer, using genetic “biomarker” results to match you to the right treatment group. It focuses first on safety, and also looks for early signs the treatment may work in specific tumor subgroups.
New Hyde Park, New YorkAges 18 years+ - NCT04996875RecruitingPhase 2
Bezuclastinib for advanced mast cell disease
This Phase 2 study tests bezuclastinib, a targeted medicine, in people with advanced systemic mastocytosis (including certain advanced forms with blood cancers). It aims to shrink measurable disease and improve symptoms, while helping people who may also need treatment for an associated blood cancer.
New York, New YorkAges 18 years+ - NCT04872543RecruitingPhase 2
Study drug for nerve tumor caused by PRC2 loss
This Phase 2 trial studies ASTX727 in people with malignant peripheral nerve sheath tumors (MPNST) that have a specific genetic change (“PRC2 loss”). It aims to shrink or control advanced tumors that have not responded to at least one standard treatment, by testing how well the drug works and is tolerated.
Commack, New YorkAges 16 years+ - NCT04752826RecruitingPhase 1/Phase 2
A new drug combo for advanced cancers
This trial tests a new experimental drug, BI-1808, alone or with an approved cancer drug called pembrolizumab (Keytruda). It's for people with advanced cancers that have stopped responding to standard treatments.
New York, New YorkAges 18 years+ - NCT04172532RecruitingPhase 1/Phase 2
New targeted drug with radiation for locally advanced pancreatic cancer
This Phase 1/2 trial tests adding peposertib, a targeted anti-cancer drug, to standard radiation for people with locally advanced pancreatic adenocarcinoma. It aims to improve control of the cancer after initial chemotherapy and determine whether the combo is safe and effective.
Buffalo, New YorkAges 18 years+ - NCT03606967RecruitingPhase 2
Individualized vaccine added to standard treatment for metastatic triple-negative breast cancer
This Phase 2 trial tests whether adding a personalized cancer vaccine to durvalumab (an immunotherapy), tremelimumab (another immunotherapy), and chemotherapy can improve outcomes for people with metastatic triple-negative breast cancer. It may help your immune system recognize your specific tumor features.
New York, New YorkAges 18 years+ - NCT07697456RecruitingPhase 2
Study of advanced therapies for Crohn's or ulcerative colitis
This study tests advanced treatments for people with moderate to severe Crohn's disease or ulcerative colitis who haven't responded to at least one previous therapy. It aims to find better options for managing these conditions.
New York, New YorkAges 18–75 - NCT06769698RecruitingPhase 2
Testing fianlimab with cemiplimab for head and neck cancer
This study compares a new combination of two drugs (fianlimab and cemiplimab) against cemiplimab alone for people with head and neck cancer that has returned or spread. It aims to see if the combination works better.
Rochester, New YorkAges 18 years+
Advanced or Metastatic Solid Tumors trials by city in New York
Where these studies are running in New York
Institutions with a site for the recruiting advanced or metastatic solid tumors studies listed above.
- Memorial Sloan Kettering Cancer Center · 8 studies
- Memorial Sloan Kettering Nassau · 4 studies
- Memorial Sloan Kettering Westchester · 4 studies
- Montefiore Medical Center · 4 studies
- Columbia University Irving Medical Center · 3 studies
- Icahn School of Medicine at Mount Sinai / Mount Sinai Hospital · 3 studies
- Memorial Sloan Kettering Commack · 3 studies
- Northwell Health · 3 studies
What taking part in a advanced or metastatic solid tumors study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Advanced or Metastatic Solid Tumors trials in other states
Common questions
- Are there advanced or metastatic solid tumors clinical trials in New York?
- Yes. We're currently tracking 582 recruiting advanced or metastatic solid tumors studies with a site in New York, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a advanced or metastatic solid tumors study in New York?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in New York to take part?
- Not necessarily. These studies have a site in New York, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a advanced or metastatic solid tumors trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New advanced or metastatic solid tumors studies open in New York regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.